Innovative Therapies for Myositis

This chapter explores the potential of JAK inhibitors, specifically upatacitinib and tofacitinib, in treating inflammatory myositis, highlighting their promising results over traditional treatments. It discusses the need for more research and the evaluation of new therapies for patients with antisynthetase syndrome and MDA5, addressing both benefits and safety concerns.